Aptimmune Biologis selected for accelerator program
The Yield Lab chose the company for development and launch of its innovative swine mucosal vaccines
Aptimmune Biologics has been selected to participate in a nine-month program designed to support emerging ag tech companies. The Yield Lab, a St. Louis-based ag technology business accelerator and investor, chose Aptimmune Biologics from among 120 applicants to participate in the program. The choice represents The Yield Lab’s first animal health investment.
Aptimmune Biologics, based in Champaign, Ill., is developing and will soon launch innovative autogenous mucosal vaccines to help producers prevent major swine viral diseases. “We are honored that The Yield Lab has chosen to invest in Aptimmune and to share its business accelerator expertise with us,” says Aaron Gilbertie, CEO of Aptimmune Biologics. “We are among a very select group of emerging ag technology companies that The Yield Lab has selected to invest in, and we believe their support and business resources will help us bring new, highly-effective animal health products to market more quickly.”
“Aptimmune is a company with extensive technical expertise, and the vaccine products they are developing have the potential to greatly improve swine health and food production in general,” says Matt Plummer, Principal at The Yield Lab. “The entire Aptimmune team has been tremendous to work with, and we believe the company is deriving value from The Yield Lab business accelerator program.”
The Yield Lab is the nation’s first and largest agriculture technology business accelerator, maintaining its investment focus entirely on early-stage development of ag tech companies that offer creative and innovative solutions to the food and agriculture industry. The Yield Lab provides mentorship, networking and funding to hand-selected companies during a nine-month period.